| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (NCT03841110) | Fate Therapeutics | 2019-02-15 |
| A Study of a Personalized Neoantigen Cancer Vaccine (NCT03639714) | Gritstone bio, Inc. | 2019-02-13 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (NCT03782207) | Hoffmann-La Roche | 2019-02-07 |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors (NCT03827837) | Jiangsu HengRui Medicine Co., Ltd. | 2019-01-23 |
| Patient-reported Outcomes in Bladder Cancer (NCT03584659) | Rigshospitalet, Denmark | 2019-01-21 |
| Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma (NCT03486197) | University of Washington | 2019-01-17 |
| Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma (NCT03788746) | AstraZeneca | 2019-01-17 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate (NCT03582475) | Jonsson Comprehensive Cancer Center | 2019-01-11 |
| A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer (NCT03809013) | RemeGen Co., Ltd. | 2019-01-07 |
| Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma (NCT03737123) | Nabil Adra | 2018-12-19 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667) | ImmunityBio, Inc. | 2018-12-11 |
| Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma (NCT03658304) | University of Florida | 2018-12-05 |
| Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer (NCT03557918) | Matthew Galsky | 2018-11-12 |
| A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer (NCT03575013) | Yousef Zakharia | 2018-10-29 |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (NCT03558503) | UroGen Pharma Ltd. | 2018-10-15 |
| A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma (NCT03676946) | Lee's Pharmaceutical Limited | 2018-10-10 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors (NCT03665285) | NextCure, Inc. | 2018-10-01 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (NCT03606174) | Mirati Therapeutics Inc. | 2018-09-11 |
| Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases (NCT03520231) | University Health Network, Toronto | 2018-09-04 |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110) | Genocea Biosciences, Inc. | 2018-08-29 |
| Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer (NCT03523572) | Daiichi Sankyo | 2018-08-02 |
| The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer (NCT03577132) | Seoul National University Hospital | 2018-08-01 |
| A Study of Personalized Neoantigen Cancer Vaccines (NCT03794128) | Gritstone bio, Inc. | 2018-07-25 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study (NCT06339138) | Mayo Clinic | 2018-06-27 |
| Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies (NCT03407976) | University of Utah | 2018-06-19 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (NCT03397394) | pharmaand GmbH | 2018-06-01 |
| INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (NCT03502785) | Inovio Pharmaceuticals | 2018-05-24 |
| Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (NCT03473756) | Bayer | 2018-05-15 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (NCT03475953) | Institut Bergonié | 2018-05-04 |
| A Study of ADXS-NEO Expressing Personalized Tumor Antigens (NCT03265080) | Advaxis, Inc. | 2018-03-28 |
| CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors (NCT03511391) | University Hospital, Ghent | 2018-03-09 |
| The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence (NCT03062059) | National Cancer Center, Korea | 2018-03-01 |
| A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina (NCT03330886) | Hoffmann-La Roche | 2018-02-09 |
| Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer (NCT03240016) | University of Michigan Rogel Cancer Center | 2018-02-08 |
| Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma (NCT03287050) | University of Michigan Rogel Cancer Center | 2018-01-24 |
| Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NCT03387761) | The Netherlands Cancer Institute | 2018-01-15 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer (NCT03507166) | RemeGen Co., Ltd. | 2017-12-28 |
| A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) (NCT03399643) | Hoffmann-La Roche | 2017-12-28 |
| Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: (NCT03548688) | British Urology Researchers in Surgical Training | 2017-12-14 |
| A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (NCT03311334) | Sumitomo Pharma America, Inc. | 2017-12-14 |
| QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (NCT03197571) | ImmunityBio, Inc. | 2017-12-01 |
| A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) (NCT03232593) | Hoffmann-La Roche | 2017-11-29 |
| Development of Diagnostics and Treatment of Urological Cancers (NCT02994758) | Helsinki University Central Hospital | 2017-11-27 |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma (NCT03291028) | Fox Chase Cancer Center | 2017-11-27 |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma (NCT03179943) | Fox Chase Cancer Center | 2017-11-27 |
| Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder (NCT03317158) | Noah Hahn, M.D. | 2017-11-21 |
| Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy (NCT03208712) | University of Michigan Rogel Cancer Center | 2017-11-01 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
| Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer (NCT03272217) | Arjun Balar, MD | 2017-09-13 |
| Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174) | Sarcoma Oncology Research Center, LLC | 2017-08-24 |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (NCT03252938) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2017-08-15 |
| UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch (NCT02643043) | Matthew Milowsky, MD | 2017-07-26 |
| The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence (NCT03209206) | Seoul National University Hospital | 2017-06-28 |
| SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma (NCT02986867) | University of Texas Southwestern Medical Center | 2017-06-13 |
| Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder (NCT02845323) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-05-16 |
| A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy (NCT03029832) | Genentech, Inc. | 2017-04-27 |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (NCT02788201) | National Cancer Institute (NCI) | 2017-03-27 |
| A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer (NCT03093922) | Memorial Sloan Kettering Cancer Center | 2017-03-22 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Water Versus Saline as Irrigation Fluid for Ureteroscopy (NCT03794102) | Emory University | 2017-01-17 |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma (NCT02887248) | SCRI Development Innovations, LLC | 2017-01-12 |
| A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies (NCT02232646) | Sumitomo Pharma America, Inc. | 2017-01-01 |
| A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (NCT02983045) | Nektar Therapeutics | 2016-12-19 |
| Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors (NCT02717156) | University of Southern California | 2016-11-21 |
| Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder (NCT02968732) | Fox Chase Cancer Center | 2016-11-11 |
| Glycosylation of Exosomes in Prostate and Urothelial Carcinoma (NCT04960956) | Indiana University | 2016-10-13 |
| MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers (NCT02989064) | Adaptimmune | 2016-10-01 |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations (NCT02795156) | SCRI Development Innovations, LLC | 2016-09-28 |
| Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy (NCT03039413) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-09-28 |
| CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma (NCT03013920) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2016-08-01 |
| Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (NCT02807636) | Hoffmann-La Roche | 2016-06-30 |
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer (NCT02769962) | National Cancer Institute (NCI) | 2016-05-09 |
| Confocal Laser Endomicroscopy in the Lower Urinary Tract (NCT03013894) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2016-03-01 |
| Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program (NCT02585362) | Kantonsspital Winterthur KSW | 2016-03-01 |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (NCT02573259) | Pfizer | 2016-02-10 |
| Predictive Factorsfor Final Pathologic Ureteral Sections (NCT03677544) | Centre Hospitalier Universitaire, Amiens | 2016-01-01 |
| Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma (NCT02535650) | Samsung Medical Center | 2015-11-12 |
| Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer (NCT02500121) | Matthew Galsky | 2015-11-11 |
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (NCT02426125) | Eli Lilly and Company | 2015-07-13 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (NCT02475213) | MacroGenics | 2015-07-01 |
| A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (NCT02479178) | BIND Therapeutics | 2015-06-01 |
| Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects (NCT02365766) | Jason R. Brown | 2015-05-27 |
| Study of the CD40 Agonistic Monoclonal Antibody APX005M (NCT02482168) | Apexigen America, Inc. | 2015-05-01 |
| Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction (NCT03280459) | Kantonsspital Winterthur KSW | 2015-01-01 |
| BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma (NCT02278978) | National Taiwan University Hospital | 2014-10-01 |
| Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes (NCT02236195) | Mirati Therapeutics Inc. | 2014-10-01 |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function (NCT02665039) | Dr Anders Ullén | 2014-04-01 |
| Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma (NCT01907308) | University of Colorado, Denver | 2014-02-01 |
| EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells (NCT01993966) | National Taiwan University Hospital | 2014-01-01 |
| Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer (NCT01780545) | Noah Hahn, M.D. | 2013-04-01 |
| The Cxbladder Monitoring Study (NCT02700659) | Pacific Edge Limited | 2013-02-04 |
| Cabozantinib for Advanced Urothelial Cancer (NCT01688999) | National Cancer Institute (NCI) | 2012-09-11 |
| Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (NCT01606345) | H. Lee Moffitt Cancer Center and Research Institute | 2012-07-01 |